98%
921
2 minutes
20
Neurotrophic factor 3 (NT-3), a potent neurotrophin, promotes neuronal survival and axonal regeneration while demonstrating a unique capacity to induce lineage-specific differentiation of pluripotent stem cells into functional neurons, underscoring its therapeutic potential in neural repair. Despite these advantages, the large-scale production of recombinant human NT-3 with preserved structure integrity and functional bioactivity remains a critical challenge. This study takes advantage of the silk gland bioreactor of silkworms for the recombinant expression of human NT-3 protein on a large scale. Our findings reveal that NT-3 was successfully expressed in the middle silk gland of silkworms and secreted into the silk fibers, achieving a yield of up to 0.5 mg of bioactive NT-3 per gram of cocoon weight. The engineered NT-3-functionalized silk material demonstrates no cytotoxicity and significantly enhanced the proliferation, migration, and differentiation of neural cells compared to natural silk protein. Importantly, this functionalized material also promotes neurite outgrowth in HT-22 cells. These results collectively underscore the high bioactivity of the recombinant human NT-3 protein produced in the silkworm silk gland. The ongoing fabrication of NT-3-incorporated silk-based materials holds considerable promise for advancing tissue engineering and nerve regeneration applications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12295520 | PMC |
http://dx.doi.org/10.3390/insects16070676 | DOI Listing |
Spinal Cord
September 2025
Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Study Design: Systematic Review OBJECTIVES: To systematically examine the use of bioengineered scaffolds, with/without bioactive agents, drugs, or cellular transplants in preclinical animal models and human studies of spinal cord injury (SCI).
Setting: Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences METHODS: A systematic review and meta-analysis was conducted following PRISMA guidelines and registered in PROSPERO (ID: CRD42023437266). A comprehensive search in MEDLINE and Embase on 8/27/2023 identified studies on scaffolds as neuroregenerative and neuroprotective treatments for SCI.
Community Dent Health
June 2025
Department of Oral and Maxillofacial Surgery, Gansu Province Hospital, Lanzhou, China.
Background: Head and neck cancer (HNC) is influenced by lipids and inflammatory factors. This study explores the causal relationship between 179 lipids, 91 inflammatory factors, and HNC using Mendelian Randomization (MR) analysis.
Method: GWAS datasets for lipids and inflammatory markers were combined with HNC data from the FinnGen Biobank.
Insects
June 2025
Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City & Southwest University, Biological Science Research Center, Southwest University, Chongqing 400715, China.
Neurotrophic factor 3 (NT-3), a potent neurotrophin, promotes neuronal survival and axonal regeneration while demonstrating a unique capacity to induce lineage-specific differentiation of pluripotent stem cells into functional neurons, underscoring its therapeutic potential in neural repair. Despite these advantages, the large-scale production of recombinant human NT-3 with preserved structure integrity and functional bioactivity remains a critical challenge. This study takes advantage of the silk gland bioreactor of silkworms for the recombinant expression of human NT-3 protein on a large scale.
View Article and Find Full Text PDFACS Chem Neurosci
August 2025
Department of Chemistry, Texas A&M University, Box 30012, College Station, Texas 77842-3012, United States.
Neurotrophins (NTs, including NGF, BDNF, NT-4, and NT-3) are extracellular cytokines which modulate the survival and growth of cells expressing tropomyosin receptor kinases (Trks) A-C. Cells which express Trks include many neural tissues. For instance, corneal nerves secrete NTs to counteract epithelium disruption.
View Article and Find Full Text PDFNeurol Sci
September 2025
School of Nursing, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
To observe the clinical efficacy of Gua Sha therapy in treating Parkinson's disease (PD) with rapid eye movement sleep behavior disorder (RBD). A total of 52 PD patients with RBD were randomly assigned to the experimental group (n = 26) and the control group (n = 26). The control group was treated with conventional anti-PD drugs, and the experimental group was treated with Gua Sha therapy based on the control group.
View Article and Find Full Text PDF